Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kalbe Farma TbkFRA:LCLA 76 EV-to-OCF is 9.97 as of Aug. 18, 2026, which is 61% below its 10-year median of 25.31. GuruFocus rates FRA:LCLA with a GF Score™ of 76/100 and a GF Value™ of €0.07. The stock has 3 warning signs investors should review. Among 1,005 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 51.04% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PT Kalbe Farma Tbk's Enterprise Value is €1,621 Mil.
PT Kalbe Farma Tbk's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €163 Mil. Therefore, PT Kalbe Farma Tbk's EV-to-OCF for today is 9.97.
The historical rank and industry rank for PT Kalbe Farma Tbk's EV-to-OCF or its related term are showing as below:
FRA:LCLA'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.98 Med: 25.31 Max: 88.32
Current: 10.38
During the past 13 years, the highest EV-to-OCF of PT Kalbe Farma Tbk was 88.32. The lowest was 8.98. And the median was 25.31.
FRA:LCLA's EV-to-OCF is ranked better than 51.04% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 11
vs FRA:LCLA: 10.38
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Kalbe Farma Tbk's PE Ratio (TTM) for today is calculated as:
PT Kalbe Farma Tbk's share price for today is €0.031.
PT Kalbe Farma Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PT Kalbe Farma Tbk EV-to-OCF Related Terms
PT Kalbe Farma Tbk EV-to-OCF Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's EV-to-OCF falls into.
PT Kalbe Farma Tbk's current Enterprise Value is €1,621 Mil.
PT Kalbe Farma Tbk's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €163 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kalbe Farma Tbk (FRA:LCLA) has a EV-to-OCF of 9.97 as of Aug. 18, 2026. This is 61% below median its historical median of 25.31. Over the past decade, PT Kalbe Farma Tbk's EV-to-OCF has ranged from 8.98 to 88.32. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #492 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 49%.
Is PT Kalbe Farma Tbk's EV-to-OCF too high?
PT Kalbe Farma Tbk's current EV-to-OCF of 9.97 is 61% below median its 10-year median of 25.31. Over the past 10 years, this metric has ranged from a low of 8.98 to a high of 88.32. The Drug Manufacturers industry median EV-to-OCF is 11.00. PT Kalbe Farma Tbk's value of 9.97 is 9.4% below this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #492 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Kalbe Farma Tbk has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #492 out of 1005 companies for EV-to-OCF. This puts PT Kalbe Farma Tbk in the upper half of its industry. The industry median EV-to-OCF is 11.00. PT Kalbe Farma Tbk's value of 9.97 is 9.4% below this benchmark. Historically, PT Kalbe Farma Tbk's own EV-to-OCF has ranged from 8.98 to 88.32 over the past decade. While the company's 10-year median is 25.31 vs. the industry median of 11.00, PT Kalbe Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.00, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current EV-to-OCF of 9.97 is 9.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current EV-to-OCF is 9.97, which is 61% below median its own 10-year median of 25.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
PT Kalbe Farma Tbk (FRA:LCLA) has a current EV-to-OCF of 9.97. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 55.7% below its estimated fair value. The current EV-to-OCF is 9.97, which is 61% below median its 10-year median of 25.31 and 9.4% below the Drug Manufacturers industry median of 11.00. PT Kalbe Farma Tbk's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current EV-to-OCF is 9.97 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 55.7% below its estimated GF Value™ of €0.07.
Key valuation signals for FRA:LCLA:
EV-to-OCF: 9.97 (61% below median its 10-year median of 25.31)
GF Value™: €0.07 vs. price of €0.03 (55.7% below fair value)
Industry Position: 9.4% below the Drug Manufacturers median (#492 of 1005)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
76GF Score
Get the complete analysis for FRA:LCLA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
